Certain Stock Options of TELA Bio, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2022.
November 13, 2022
Share
Certain Stock Options of TELA Bio, Inc. are subject to a Lock-Up Agreement Ending on 14-NOV-2022. These Stock Options will be under lockup for 91 days starting from 15-AUG-2022 to 14-NOV-2022.
Details:
Executive officers and directors have agreed, subject to specified exceptions, not to directly or indirectly, sell, offer to sell, contract to sell or lend, effect any short sale, establish or increase any put equivalent position or liquidate or decrease any call equivalent position, pledge, hypothecate or grant any security interest in, enter into a swap, hedge or similar arrangement that transfers the economic risk of ownership of, or otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially; or publicly announce an intention to do any of the foregoing for a period of 90 days after the date of this prospectus supplement without the prior written consent of Lake Street Capital Markets, LLC.
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.